---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-26-000032"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:40:01.770872+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Autolus reports FY2025 AUCATZYL net revenue $74.3M; guides FY2026 $120-135M

## Summary
- Q4 2025 AUCATZYL net revenue $23.3M; full-year $74.3M, primarily from U.S. sales.
- FY2025 net loss $287.5M ($1.08/share); cash & equivalents $300.7M at Dec 31.
- FY2026 revenue guidance $120-135M; expects shift to positive gross margin in 2026.
- UK launch commenced January 2026 after NICE evaluation; ROCCA real-world data confirm safety/efficacy.
- Pipeline: initial obe-cel data in progressive MS (BOBCAT) and AL amyloidosis (ALARIC) expected YE 2026.

## SEC filing metadata
- accession: 0001730463-26-000032
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000032/0001730463-26-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000032/autl-20260327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-26-000032
- JSON: https://secwatch.observer/filing/0001730463-26-000032.json
- Plain text: https://secwatch.observer/filing/0001730463-26-000032.txt

## Key facts
- Earnings Releases
  Autolus Therapeutics plc reported the quarter and full year ended December 31, 2025 results: revenue $23.3 million. Guidance reaffirmed.
  - Period: the quarter and full year ended December 31, 2025
  - Revenue: $23.3 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates March 27, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000032/0001730463-26-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.